Becton Dickinson and Co (NYSE:BDX) Shares Acquired by Tealwood Asset Management Inc.

Tealwood Asset Management Inc. raised its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 1.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,488 shares of the medical instruments supplier’s stock after purchasing an additional 155 shares during the quarter. Tealwood Asset Management Inc.’s holdings in Becton Dickinson and were worth $2,139,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. FMR LLC increased its stake in shares of Becton Dickinson and by 5.0% in the first quarter. FMR LLC now owns 17,835,000 shares of the medical instruments supplier’s stock worth $4,453,934,000 after acquiring an additional 842,590 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Becton Dickinson and by 10.4% in the first quarter. JPMorgan Chase & Co. now owns 4,418,870 shares of the medical instruments supplier’s stock worth $1,103,526,000 after acquiring an additional 416,459 shares during the period. Fundsmith LLP increased its stake in shares of Becton Dickinson and by 0.9% in the first quarter. Fundsmith LLP now owns 3,771,159 shares of the medical instruments supplier’s stock worth $941,772,000 after acquiring an additional 35,453 shares during the period. Northern Trust Corp increased its stake in shares of Becton Dickinson and by 0.7% in the first quarter. Northern Trust Corp now owns 3,223,811 shares of the medical instruments supplier’s stock worth $805,082,000 after acquiring an additional 23,645 shares during the period. Finally, Geode Capital Management LLC increased its stake in shares of Becton Dickinson and by 7.5% in the fourth quarter. Geode Capital Management LLC now owns 3,208,583 shares of the medical instruments supplier’s stock worth $721,582,000 after acquiring an additional 223,215 shares during the period. Institutional investors and hedge funds own 82.82% of the company’s stock.

Shares of NYSE:BDX traded up $1.51 during midday trading on Thursday, hitting $254.88. The company’s stock had a trading volume of 49,727 shares, compared to its average volume of 1,097,510. The business’s 50 day simple moving average is $251.72 and its 200 day simple moving average is $244.39. The company has a debt-to-equity ratio of 0.84, a quick ratio of 0.67 and a current ratio of 1.09. The company has a market cap of $67.89 billion, a P/E ratio of 23.15, a price-to-earnings-growth ratio of 1.83 and a beta of 1.11. Becton Dickinson and Co has a 12-month low of $208.62 and a 12-month high of $265.87.

Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Tuesday, August 6th. The medical instruments supplier reported $3.08 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.05 by $0.03. The firm had revenue of $4.35 billion for the quarter, compared to the consensus estimate of $4.37 billion. Becton Dickinson and had a net margin of 5.02% and a return on equity of 14.78%. The company’s revenue for the quarter was up 1.7% on a year-over-year basis. During the same period last year, the firm posted $2.91 earnings per share. On average, sell-side analysts predict that Becton Dickinson and Co will post 11.68 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 9th will be paid a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 1.21%. The ex-dividend date of this dividend is Friday, September 6th. Becton Dickinson and’s dividend payout ratio (DPR) is presently 27.97%.

In other Becton Dickinson and news, insider James C. Lim sold 1,929 shares of Becton Dickinson and stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $252.01, for a total transaction of $486,127.29. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Patrick Kaltenbach sold 275 shares of Becton Dickinson and stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $235.00, for a total transaction of $64,625.00. Following the transaction, the executive vice president now directly owns 16,482 shares in the company, valued at $3,873,270. The disclosure for this sale can be found here. Insiders have sold 8,444 shares of company stock worth $2,061,288 over the last ninety days. 0.12% of the stock is owned by insiders.

A number of analysts have recently weighed in on the stock. Piper Jaffray Companies cut their price objective on shares of Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. Barclays raised shares of Becton Dickinson and from an “equal weight” rating to an “overweight” rating and set a $266.00 price objective on the stock in a report on Monday, May 13th. ValuEngine downgraded shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Raymond James increased their price objective on shares of Becton Dickinson and from $265.00 to $288.00 and gave the company a “strong-buy” rating in a report on Friday, June 28th. Finally, KeyCorp reaffirmed an “overweight” rating and set a $262.00 price objective (down from $273.00) on shares of Becton Dickinson and in a report on Friday, May 10th. Five analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Becton Dickinson and has a consensus rating of “Buy” and a consensus price target of $264.27.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

See Also: What is meant by holder of record?

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.